scholarly journals Withdrawn: Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice

2009 ◽  
Vol 11 (2) ◽  
pp. 150-159 ◽  
Author(s):  
Yaoming Li ◽  
Jing Ye ◽  
Shengbo Cao ◽  
Shaobo Xiao ◽  
Qian Zhao ◽  
...  
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Envelope Protein ◽  
Protective Immunity ◽  
Encephalitis Virus

Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus

2007 ◽  
Vol 30 (2) ◽  
pp. 205-214 ◽  
Author(s):  
Cheng-Wen Lin ◽  
Kuang-Ting Liu ◽  
Hong-Da Huang ◽  
Wei-June Chen
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Protective Immunity ◽  
Encephalitis Virus ◽  
Ns1 Protein ◽  
E Coli

The pre membrane and envelope protein is the crucial virulence determinant of Japanese encephalitis virus

2020 ◽  
Vol 148 ◽  
pp. 104492
Author(s):  
Sheng-ling Leng ◽  
Rong Huang ◽  
Ya-nan Feng ◽  
Li-juan Peng ◽  
Jian Yang ◽  
...  
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Envelope Protein ◽  
Encephalitis Virus ◽  
Virulence Determinant

scholarly journals Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus

2008 ◽  
Vol 83 (6) ◽  
pp. 2436-2445 ◽  
Author(s):  
Mario Lobigs ◽  
Maximilian Larena ◽  
Mohammed Alsharifi ◽  
Eva Lee ◽  
Megan Pavy
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Protective Immunity ◽  
Encephalitis Virus ◽  
Type I ◽  
Murray Valley Encephalitis Virus ◽  
Lethal Challenge ◽  
Live Virus ◽  
Immunodeficient Mice ◽  
The Cross

ABSTRACT The Japanese encephalitis virus (JEV) serocomplex, which also includes Murray Valley encephalitis virus (MVEV), is a group of antigenically closely related, mosquito-borne flaviviruses that are responsible for severe encephalitic disease in humans. While vaccines against the prominent members of this serocomplex are available or under development, it is unlikely that they will be produced specifically against those viruses which cause less-frequent disease, such as MVEV. Here we have evaluated the cross-protective values of an inactivated JEV vaccine (JE-VAX) and a live chimeric JEV vaccine (ChimeriVax-JE) against MVEV in two mouse models of flaviviral encephalitis. We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (≥5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. Our results suggest that the live chimeric JEV vaccine will protect against other viruses belonging to the JEV serocomplex, consistent with the observation of cross-protection following live virus infections.

Characterization of Japanese encephalitis virus envelope protein expressed by recombinant baculoviruses

Virology ◽  
1989 ◽  
Vol 173 (2) ◽  
pp. 674-682 ◽  
Author(s):  
Yoshiharu Matsuura ◽  
Michiko Miyamoto ◽  
Takanori Sato ◽  
Chiharu Morita ◽  
Kotaro Yasui
Keyword(s):  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Envelope Protein ◽  
Encephalitis Virus ◽  
Recombinant Baculoviruses ◽  
Virus Envelope ◽  
Virus Envelope Protein
Sign in / Sign up

Export Citation Format

Share Document